Pharmacovigilance of obeticholic acid: An analysis of the Food and Drug Administration Adverse Event Reporting System database

Documenti analoghi

• Cardiovascular events of Bruton's tyrosine kinase inhibitors: A real‐world study based on the United States Food and Drug Administration Adverse Event Reporting System database
  di: Zeng‐Xiang Zhao, et al.
  Pubblicazione: (2024)
• The safety profile of usage of glucagon‐like peptide‐1 receptor agonists in pregnancy: A pharmacovigilance analysis based on the Food and Drug Administration Adverse Event Reporting System
  di: Jianxing Zhou, et al.
  Pubblicazione: (2024)
• Disproportionality analysis of cardiac adverse events associated with lenvatinib using the Japanese Adverse Drug Event Report database
  di: Yuko Kanbayashi, et al.
  Pubblicazione: (2024)
• Comprehensive safety assessment of ribociclib: A real‐world analysis using the FDA Adverse Event Reporting System (FAERS) database
  di: Lan Luo, et al.
  Pubblicazione: (2025)
• Effects of age, sex, daily dose, comorbidity and co‐medication on venlafaxine‐associated cardiovascular adverse events: A pharmacovigilance analysis of the FDA Adverse Event Reporting System database
  di: Zhanzhang Wang, et al.
  Pubblicazione: (2024)